NR2F6 and neoplasm: Nr2f6-deficient mice were significantly more resistant to development of MCA-induced sarcoma than wild-type mice (Fig. 1a) and exhibited reduced tumor growth during challenge with a primary sarcoma cell line derived from MCA-treated wild-type mice (Fig. 1b, c).